Loading...
XSHE
002737
Market cap1.08bUSD
Jul 10, Last price  
12.53CNY
1D
0.97%
1Q
2.29%
Jan 2017
-25.62%
IPO
-13.38%
Name

Sunflower Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002737 chart
P/E
—
P/S
3.16
EPS
—
Div Yield, %
3.99%
Shrs. gr., 5y
0.31%
Rev. gr., 5y
-7.71%
Revenues
2.32b
-31.36%
1,559,003,6041,769,952,9922,180,932,0932,718,760,4813,034,770,4843,363,581,1073,855,119,8114,471,756,2774,371,413,6403,461,888,3464,460,899,8645,094,511,3195,700,286,7453,377,047,6762,317,958,832
Net income
-258m
L
190,855,995234,241,123262,935,154301,127,659306,600,003303,015,580423,996,623563,277,157565,422,023584,454,191704,737,999867,222,0281,119,142,046492,045,429-257,827,574
CFO
575m
P
257,602,550327,310,490293,341,828403,225,247125,840,223341,231,457558,770,770866,207,292981,327,6771,169,867,011865,229,4641,970,785,872923,300,476-307,480,137574,965,610
Dividend
Jul 18, 20250.5 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sunflower Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the comprehensive process of traditional Chinese medicine (TCM), covering everything from research and development to production and market distribution within China. The company's product range also extends to include chemical, biological, and health-focused pharmaceuticals. These diverse medications address a broad spectrum of medical needs, providing solutions in areas such as pediatrics, gynecology, digestive system ailments, respiratory issues including the common cold, conditions related to rheumatism and bone health, and cardiovascular and cerebrovascular disorders. The company's goods are sold under its established brands, "Sunflower" and "Little Sunflower." With its headquarters located in Harbin, China, Sunflower Pharmaceutical Group was founded in 2005.
URL
https://www.kuihuayaoye.com/
IPO date
Dec 30, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT